PMID- 10499529
OWN - NLM
STAT- MEDLINE
DCOM- 19991012
LR  - 20181217
IS  - 0013-7227 (Print)
IS  - 0013-7227 (Linking)
VI  - 140
IP  - 10
DP  - 1999 Oct
TI  - An insulinotropic effect of vitamin D analog with increasing intracellular Ca2+ 
      concentration in pancreatic beta-cells through nongenomic signal transduction.
PG  - 4706-12
AB  - The effect of 1alpha,25-dihydroxylumisterol3 (1alpha,25(OH)2lumisterol3) on 
      insulin release from rat pancreatic beta-cells was measured to investigate the 
      nongenomic action of vitamin D via the putative membrane vitamin D receptor 
      (mVDR). 1Alpha,25(OH)2lumisterol3, a specific agonist of mVDR, dose-dependently 
      augmented 16.7 mM glucose-induced insulin release from rat pancreatic islets and 
      increased the intracellular Ca2+ concentration ([Ca2+]i), though not increasing 
      Ca2+ efficacy in the exocytotic system. These effects were completely abolished 
      by an antagonist of mVDR, 1beta,25-dihydroxyvitamin D3 (1beta,25(OH)2D3), or by a 
      blocker of voltage-dependent Ca2+ channels, nitrendipine. Moreover, both [Ca2+]i 
      elevation, caused by membrane depolarization, and sufficient intracellular 
      glucose metabolism are required for the expression of these effects. 
      1Alpha,25(OH)2lumisterol3, therefore, has a rapid insulinotropic effect, through 
      nongenomic signal transduction via mVDR, that would be dependent on the 
      augmentation of Ca2+ influx through voltage-dependent Ca2+ channels on the plasma 
      membrane, being also linked to metabolic signals derived from glucose in 
      pancreatic beta-cells. However, further investigations will be needed to discuss 
      physiologically the meaning of insulinotropic effects of vitamin D through mVDR.
FAU - Kajikawa, M
AU  - Kajikawa M
AD  - Department of Metabolism and Clinical Nutrition, Graduate School of Medicine, 
      Kyoto University, Japan. kajikawa@metab.kuhp.kyoto-u.ac.jp
FAU - Ishida, H
AU  - Ishida H
FAU - Fujimoto, S
AU  - Fujimoto S
FAU - Mukai, E
AU  - Mukai E
FAU - Nishimura, M
AU  - Nishimura M
FAU - Fujita, J
AU  - Fujita J
FAU - Tsuura, Y
AU  - Tsuura Y
FAU - Okamoto, Y
AU  - Okamoto Y
FAU - Norman, A W
AU  - Norman AW
FAU - Seino, Y
AU  - Seino Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Endocrinology
JT  - Endocrinology
JID - 0375040
RN  - 0 (1,25-dihydroxylumisterol(3))
RN  - 0 (Insulin)
RN  - 1406-16-2 (Vitamin D)
RN  - IY9XDZ35W2 (Glucose)
RN  - O5CB12L4FN (Diazoxide)
RN  - RWP5GA015D (Potassium)
RN  - SY7Q814VUP (Calcium)
RN  - Z30RAY509F (Ergosterol)
SB  - IM
MH  - Animals
MH  - Calcium/*metabolism
MH  - Diazoxide/pharmacology
MH  - Electric Stimulation
MH  - Ergosterol/*analogs & derivatives/pharmacology
MH  - Glucose/pharmacology
MH  - Insulin/*metabolism
MH  - Insulin Secretion
MH  - Intracellular Membranes/*metabolism
MH  - Islets of Langerhans/drug effects/*metabolism
MH  - Male
MH  - Osmolar Concentration
MH  - Permeability
MH  - Potassium/pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Signal Transduction/*physiology
MH  - Vitamin D/*analogs & derivatives
EDAT- 1999/09/28 00:00
MHDA- 1999/09/28 00:01
CRDT- 1999/09/28 00:00
PHST- 1999/09/28 00:00 [pubmed]
PHST- 1999/09/28 00:01 [medline]
PHST- 1999/09/28 00:00 [entrez]
AID - 10.1210/endo.140.10.7025 [doi]
PST - ppublish
SO  - Endocrinology. 1999 Oct;140(10):4706-12. doi: 10.1210/endo.140.10.7025.